Development of a novel vaccine therapy using nanoparticles and cross-presentation machinery

• Project/Area Number: 25461186
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Respiratory organ internal medicine
• Research Institution: Hamamatsu University School of Medicine
• Principal Investigator: Enomoto Noriyuki 浜松医科大学, 医学部附属病院, 講師 (50436961)
• Co-Investigator(Kenkyū-buntansha): Suda Takafumi 浜松医科大学, 医学部, 教授 (30291397)
• Project Period (FY): 2013-04-01 – 2016-03-31
• Project Status: Completed (Fiscal Year 2015)
• Budget Amount: ¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000); Fiscal Year 2015: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000); Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000); Fiscal Year 2013: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
• Keywords: 気管支喘息 / ワクチン療法 / ナノ粒子 / 樹状細胞 / 細胞障害性T細胞 / クロスプレゼンテーション

Outline of Final Research Achievements

In this study, nanoparticle, which consists of polylactic coglycolic acid (PLGA), was used to induce allergen specific cytotoxic T-lymphocytes (CTL). PLGA facilitates the induction of CTL via cross-presentation machinery in antigen-presenting cells (APC), and these CTL can kill dendritic cell (DC) that plays a role in bronchial asthma.
We found PLGA efficiently induced ovalbumin (OVA)-specific CTL via antigen-presenting cells in vitro. Next, PLGA/OVA was intranasally administered to OVA-induced asthma model mice. PLGA/OVA reduced eosinophil number in bronchoalveolar lavage compared to that after treatment with OVA alone. However, PLGA/OVA could not significantly reduce eosinophil number or induce allergen-specific CTL compared to those of untreated mice. There is a possibility that more manipulation of PLGA/OVA is necessary to improve the delivery and phagocytosis of allergen in APC and to facilitate cross-presentation in vivo.

Research Products

• [Journal Article] Amount of elastic fibers predicts prognosis of idiopathic pulmonary fibrosis. (2013)
  • Author(s): Enomoto N, Suda T, Kono M, Kaida Y, Hashimoto D, Fujisawa T, Inui N, Nakamura Y, Imokawa S, Funai K, Chida K.
  • Journal Title: Respir Med. Volume: 107 Issue: 10 Pages: 1608-1616
  • DOI: 10.1016/j.rmed.2013.08.008
  • Peer Reviewed
• [Presentation] Idiopathic pleuroparenchymal fibroelastosis (IPPFE): Comparison of clinico-pathological findings with idiopathic pulmonary fibrosis (IPF) (2013)
  • Author(s): Noriyuki Enomoto
  • Organizer: Annual meeting of American Thoracic Society
  • Place of Presentation: Philadelphia